Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 11
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 12
Equity Offering 13
Intellipharmaceutics Raises USD14.3 Million in Public Offering of Shares and Warrants 13
Intellipharmaceutics Raises USD1.8 Million in Private Placement of Shares 15
Intellipharmaceutics Raises USD3.5 Million in Private Placement of Shares and Warrants 16
Intellipharmaceutics Raises USD4 Million in Private Placement of Shares 17
Intellipharmaceutics International to Raise up to USD4 Million in Public Offering of Shares 19
Intellipharmaceutics International Raises USD5.2 Million in Public Offering of Units 20
Intellipharmaceutics International Announces Public Offering Of Shares For Up To US$17 Million 22
Intellipharmaceutics International Completes Public Offering Of Units For US$3 Million 23
Intellipharmaceutics International Completes Private Placement Of Units For US$3 Million 24
Intellipharmaceutics International Completes Public Offering Of Common Stock For US$5 Million 25
Debt Offering 27
Intellipharmaceutics Raises USD0.5 Million in Private Placement of 10% Debenture Due 2030 27
Intellipharmaceutics International Completes Private Placement Of Debentures Due 2015 For US$1.5 Million 28
Intellipharmaceutics International Inc – Key Competitors 29
Intellipharmaceutics International Inc – Key Employees 30
Intellipharmaceutics International Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Oct 15, 2018: Intellipharmaceutics announces third quarter 2018 results 32
Jul 16, 2018: Intellipharmaceutics reports second quarter 2018 results 35
Apr 16, 2018: Intellipharmaceutics Reports First Quarter 2018 Results 38
Oct 10, 2017: Intellipharmaceutics Announces Third Quarter 2017 Results 41
Jul 11, 2017: Intellipharmaceutics Announces Second Quarter 2017 Results 43
Apr 11, 2017: Intellipharmaceutics Announces First Quarter 2017 Results 45
Feb 10, 2017: Intellipharmaceutics Announces 2016 Year End Results 48
Corporate Communications 51
Nov 05, 2018: Intellipharmaceutics: Resignation of Chief Financial Officer 51
Jun 08, 2018: Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ 52
Apr 27, 2018: Intellipharmaceutics Files Appeal to Nasdaq Delisting Determination 53
Sep 01, 2017: Intellipharmaceutics Appoints New Chief Financial Officer 54
Aug 08, 2017: Intellipharmaceutics Announces Resignation of CFO 55
Legal and Regulatory 56
May 26, 2017: Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement 56
Product News 57
09/05/2017: Intellipharmaceutics Provides Operational Update 57
07/31/2017: Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit 59
05/08/2018: Intellipharmaceutics Announces Start of Intranasal Human Abuse Liability Studies for Oxycodone ER 60
Product Approvals 61
Feb 09, 2018: Intellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development Program 61
Sep 25, 2017: Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista NDA 62
Jul 26, 2017: Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 63
Jun 30, 2017: Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 64
Feb 02, 2017: Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 65
Other Significant Developments 66
Jan 24, 2018: Intellipharmaceutics Provides Operational Update 66
Mar 16, 2017: Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI” 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Intellipharmaceutics International Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 11
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 12
Intellipharmaceutics Raises USD14.3 Million in Public Offering of Shares and Warrants 13
Intellipharmaceutics Raises USD1.8 Million in Private Placement of Shares 15
Intellipharmaceutics Raises USD3.5 Million in Private Placement of Shares and Warrants 16
Intellipharmaceutics Raises USD4 Million in Private Placement of Shares 17
Intellipharmaceutics International to Raise up to USD4 Million in Public Offering of Shares 19
Intellipharmaceutics International Raises USD5.2 Million in Public Offering of Units 20
Intellipharmaceutics International Announces Public Offering Of Shares For Up To US$17 Million 22
Intellipharmaceutics International Completes Public Offering Of Units For US$3 Million 23
Intellipharmaceutics International Completes Private Placement Of Units For US$3 Million 24
Intellipharmaceutics International Completes Public Offering Of Common Stock For US$5 Million 25
Intellipharmaceutics Raises USD0.5 Million in Private Placement of 10% Debenture Due 2030 27
Intellipharmaceutics International Completes Private Placement Of Debentures Due 2015 For US$1.5 Million 28
Intellipharmaceutics International Inc, Key Competitors 29
Intellipharmaceutics International Inc, Key Employees 30
Intellipharmaceutics International Inc, Subsidiaries 31
List of Figures
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9